15 May 2025
LungLife AI, Inc.
(the "Company" or "LungLife")
Block Admission Six Monthly Return
LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, makes the following six monthly update on its block admission pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies:
| Name of Company: |
LungLife AI, Inc. |
|||
| Name of scheme: |
1. 2010 Stock Incentive Plan 2. 2020 Stock Incentive Plan 3. 2021 Omnibus Long-Term Incentive Plan |
|||
| Number and class of securities originally admitted: |
1,356,139 common shares of US $0.0001 each |
|||
| Date of admission: |
15 November 2021 |
|||
| Period of return: |
From: |
15 November 2024 |
To: |
15 May 2025 |
| Balance of unallotted securities under scheme(s) from previous return: |
1. 475,583 2. 201,374 3. 673,990 |
|||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): |
1. NIL 2. NIL 3. NIL |
|||
| Less: Number of securities issued/allotted under scheme(s) during period: |
1. NIL 2. NIL 3. NIL |
|||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period : |
1. 475,583 2. 201,374 3. 673,990 |
|||
| Total number of securities in issue at the end of the period |
30,658,603 |
|||
| Name of contact: |
David Anderson, Chief Financial Officer |
| Telephone number of contact: |
+44 (0)20 7933 8780 |
For further information please contact:
| LungLife AI, Inc. |
||
| Paul Pagano, CEO |
||
| David Anderson, CFO |
|
|
|
|
|
|
| Allenby Capital Limited Nominated Adviser and Joint Broker Alex Brearley / Lauren Wright - Corporate Finance Matt Butlin / Guy McDougall - Equity Sales & Corporate Broking |
Tel: +44 (0)20 3328 5656
|
|
|
|
|
|
| Goodbody (Joint Broker) |
Tel: +44 (0) 20 3841 6202 |
|
| Tom Nicholson / Cameron Duncan |
|
|
|
|
|
|
About LungLife
LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB® test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com.
Our Purpose is to be a driving force in the early detection to lung cancer. And our Vision is to invert the 20:80 ratio such that in years to come at least 80% of lung cancer is detected early.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.